Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Sugen (SUGN) -- Ignore unavailable to you. Want to Upgrade?

To: gao seng who wrote (515)	7/19/1999 4:57:00 PM
From: scaram(o)uche	Read Replies (2) \| Respond to of 550

blast from the past..... sciencedaily.com

To: gao seng who wrote (515)	7/20/1999 12:45:00 AM
From: Miljenko Zuanic	Read Replies (1) \| Respond to of 550

GS: Radiation was, is and will continue to be one of the cornerstone in cancer therapy. However, the point is to delivery radiation specifically to cancer cells while spear healthy one if possible. So, reducing radiation dose by applying radio-enhencer (PCYC for instance) is one way. Another one is adding other agent which will bust radiation damage to cancer cells (also by reducing their ability to re-growth vasculature, anti-growth factors) without significantly increase combined toxicity. The main objective here is not to increase response rate (it is noteworthy but not detrimental), it is to increase disease progression free time and overall survival rate/time. Many agents are now in trials in combination with radiation. This will not be simple trials and will need time to show benefit to cancer patients (specially for prophylactic agents). Thalidomide in combination with radiation for multiple cancer indication (in PII, sponsored by NCI) may be first one which may have survival rate positive outcome. IMCL C225 did have good results in PI for response rate in combination with radiation (H&N C), but survival rate and time wasn't seriously considered. Anti-growth factors approach after radiation seams natural choice, imo. Miljenko